Books in Drug discovery

1-10 of 71 results in All results

A Pharmacology Primer

4th Edition
Terry P. Kenakin
Terry P. Kenakin
March 26, 2014

Hardback
9 7 8 - 0 - 1 2 - 4 0 7 6 6 3 - 1
eBook
9 7 8 - 0 - 1 2 - 4 0 7 6 8 9 - 1

A Pharmacology Primer: Techniques for More Effective and Strategic Drug Discovery, 4th Edition features the latest ideas and research about the application of pharmacology to the process of drug discovery to equip readers with a deeper understanding of the complex and rapid changes in this field. Written by well-respected pharmacologist, Terry P. Kenakin, this primer is an indispensable resource for all those involved in drug discovery. This edition has been thoroughly revised to include material on data-driven drug discovery, biased signaling, structure-based drug design, drug activity screening, drug development (including pharmacokinetics and safety Pharmacology), and much more. With more color illustrations, examples, and exercises throughout, this book remains a top reference for all industry and academic scientists and students directly involved in drug discovery, or pharmacologic research.

Advances in Cancer Research

1st Edition
Bozzano G Luisa
Bozzano G Luisa
May 28, 1977

eBook
9 7 8 - 0 - 0 8 - 0 5 6 2 0 7 - 0

Advances in Cancer Research

1st Edition
George F. Vande Woude, Garret Hampton + 2 more
George F. Vande Woude, Garret Hampton, Karol Sikora + 1 more
December 15, 2006

Hardback
9 7 8 - 0 - 1 2 - 0 0 6 6 9 6 - 4
eBook
9 7 8 - 0 - 0 8 - 0 4 7 1 0 1 - 3

The Advances in Cancer Research series provides invaluable information on the exciting and fast-moving field of cancer research. This volume stands as the first ever thematic volume in the series, focusing on the topic of genomics in cancer drug development. The chapters included in this book represent the cutting-edge information in the field and span such topics as Mass Spectrometry: Uncovering the Cancer Proteome for Diagnostics; Biomarker Discovery in Epithelial Ovarian Cancer by Genomic Approaches; The Application of siRNA Technology to Cancer Biology Discovery; Ribozyme Technology for Cancer Gene Target Identification and Validation; Cancer Cell-Based Genomic and Small Molecule Screens; Tumour Antigens as Surrogate Markers and Targets for Therapy and Vaccines; Practices and Pitfalls of Mouse Cancer Models in Drug Discovery; Biomarker Assay Translation from Discovery to Clinical Studies in Cancer Drug Development – Quantification of Emerging Protein Biomarkers; Molecular Optical Imaging of Therapeutic Targets of Cancer; Cancer Drug Approval in the United States, Europe and Japan.

Advances in Drug Research

1st Edition
Bernard Testa + 1 more
Bernard Testa and Urs A. Meyer
July 2, 1996

Hardback
9 7 8 - 0 - 1 2 - 0 1 3 3 2 8 - 4
eBook
9 7 8 - 0 - 0 8 - 0 5 2 6 7 1 - 3

This volume continues the trend for Advances in Drug Research of shorter, but more frequent volumes. In line with the tradition of the series, chapters on general themes are interspersed with chapters on specific drug classes and targets.

Advances in Drug Research

1st Edition
Bernard Testa + 1 more
Bernard Testa and Urs A. Meyer
July 21, 1997

eBook
9 7 8 - 0 - 0 8 - 0 5 2 6 7 2 - 0

Advances in Drug Research

1st Edition
Bernard Testa + 1 more
Bernard Testa and Urs A. Meyer
August 12, 1997

eBook
9 7 8 - 0 - 0 8 - 0 5 2 6 2 8 - 7

Animal and Translational Models for CNS Drug Discovery

1st Edition
Robert A. McArthur + 1 more
Robert A. McArthur and Franco Borsini
October 21, 2008

eBook
9 7 8 - 0 - 0 8 - 0 9 2 0 4 1 - 2

Animal and Translational Models for CNS Drug Discovery combines the experience of academic, clinical and pharmaceutical neuroscientists in a unique collaborative approach to provide a greater understanding of the relevance of animal models of neuropsychiatric disorders and their role as translational tools for the discovery of CNS drugs being developed for the treatment of these disorders. The focus of this three-volume series of essays is to present a consensual picture of the translational value of animal models from leading experts actively involved in the use of animal models for understanding fundamental neurobiology of CNS disorders and the application of this knowledge to CNS drug discovery, and clinical investigators involved in clinical trials, drug development and eventual registration of novel pharmaceuticals. Each volume of the Animal and Translational Models for CNS Drug Discovery series is dedicated to the development and use of animal models in key therapeutic areas in psychiatric, neurologic and reward deficit disorders. Each volume has introductory chapters expressing the view of the role and relevance of animal models for CNS drug discovery and development from the perspective of (a) academic basic neuroscientific research, (b) applied pharmaceutical drug discovery and development, and (c) issues of clinical trial design and regulatory agencies limitations. Each volume examines the rationale, use, robustness and limitations of animal models in relevant therapeutic areas and discusses the use of animal models for target identification and validation. The clinical relevance of animal models is discussed in terms of major limitations in cross-species comparisons, clinical trial design of drug candidates, and how clinical trial endpoints could be improved. The aim of this series of volumes on Animal and Translational Models for CNS Drug Discovery is to identify and provide common endpoints between species that can serve to inform both the clinic and the bench with the information needed to accelerate clinically-effective CNS drug discovery.

Image - Animal and Translational Models for CNS Drug Discovery

Animal and Translational Models for CNS Drug Discovery: Neurological Disorders

1st Edition
Robert A. McArthur + 1 more
Robert A. McArthur and Franco Borsini
October 6, 2008

Hardback
9 7 8 - 0 - 1 2 - 3 7 3 8 5 5 - 4
eBook
9 7 8 - 0 - 0 8 - 0 9 2 0 3 8 - 2

Neurological Disorders is written for researchers in both academia and the pharmaceutical industry who use animal models in research and development of drugs for neurological disorders such as neurofibromatosis, Alzheimer’s disease, Parkinson’s disease, Huntington disease, ALS, and the epilepsies. Neurological Disorders has introductory chapters expressing the view of the role and relevance of animal models for drug discovery and development for the treatment of psychiatric disorders from the perspective of (a) academic basic neuroscientific research, (b) applied pharmaceutical drug discovery and development, and (c) issues of clinical trial design and regulatory agencies limitations. Each volume examines the rationale, use, robustness and limitations of animal models in each therapeutic area covered and discuss the use of animal models for target identification and validation. The clinical relevance of animal models is discussed in terms of major limitations in cross-species comparisons, clinical trial design of drug candidates, and how clinical trial endpoints could be improved. The aim of this series of volumes on Animal and Translational Models for CNS Drug Discovery is to identify and provide common endpoints between species that can serve to inform both the clinic and the bench with the information needed to accelerate clinically-effective CNS drug discovery. This is the second volume in the three volume-set, Animal and Translational Models for CNS Drug Discovery 978-0-12-373861-5, which is also available for purchase individually.

Image - Animal and Translational Models for CNS Drug Discovery: Neurological Disorders

Animal and Translational Models for CNS Drug Discovery: Psychiatric Disorders

1st Edition
Robert A. McArthur + 1 more
Robert A. McArthur and Franco Borsini
October 6, 2008

Hardback
9 7 8 - 0 - 1 2 - 3 7 3 8 5 6 - 1
eBook
9 7 8 - 0 - 0 8 - 0 9 2 0 3 9 - 9

Psychiatric Disorders is written for researchers in both academia and the pharmaceutical industry who use animal models in research and development of drugs for psychiatric disorders such as anxiety, obsessive-compulsive disorder, depression, schizophrenia, bipolar disorder, ADHD, and autistic spectrum disorder. Psychiatric Disorders has introductory chapters expressing the view of the role and relevance of animal models for drug discovery and development for the treatment of psychiatric disorders from the perspective of (a) academic basic neuroscientific research, (b) applied pharmaceutical drug discovery and development, and (c) issues of clinical trial design and regulatory agencies limitations. Each volume examines the rationale, use, robustness and limitations of animal models in each therapeutic area covered and discuss the use of animal models for target identification and validation. The clinical relevance of animal models is discussed in terms of major limitations in cross-species comparisons, clinical trial design of drug candidates, and how clinical trial endpoints could be improved. The aim of this series of volumes on Animal and Translational Models for CNS Drug Discovery is to identify and provide common endpoints between species that can serve to inform both the clinic and the bench with the information needed to accelerate clinically-effective CNS drug discovery. This is the first volume in the three volume-set, Animal and Translational Models for CNS Drug Discovery 978-0-12-373861-5, and is also available for purchase individually.

Image - Animal and Translational Models for CNS Drug Discovery: Psychiatric Disorders

Animal and Translational Models for CNS Drug Discovery: Reward Deficit Disorders

1st Edition
Robert A. McArthur + 1 more
Robert A. McArthur and Franco Borsini
October 6, 2008

Hardback
9 7 8 - 0 - 1 2 - 3 7 3 8 6 0 - 8
eBook
9 7 8 - 0 - 0 8 - 0 9 2 0 4 0 - 5

Reward Deficit Disorders is written for researchers in both academia and the pharmaceutical industry who use animal models in research and development of drugs for reward deficit disorders such as alcohol dependence, nicotine dependence, heroin and cocaine addiction, obesity, and gambling and impulse control disorders. Reward Deficit Disorders has introductory chapters expressing the view of the role and relevance of animal models for drug discovery and development for the treatment of psychiatric disorders from the perspective of (a) academic basic neuroscientific research, (b) applied pharmaceutical drug discovery and development, and (c) issues of clinical trial design and regulatory agencies limitations. Each volume examines the rationale, use, robustness and limitations of animal models in each therapeutic area covered and discuss the use of animal models for target identification and validation. The clinical relevance of animal models is discussed in terms of major limitations in cross-species comparisons, clinical trial design of drug candidates, and how clinical trial endpoints could be improved. Reward Deficit Disorders also has a section dedicated to the specifics of the regulatory aspects to abuse liability testing. The aim of this series of volumes on Animal and Translational Models for CNS Drug Discovery is to identify and provide common endpoints between species that can serve to inform both the clinic and the bench with the information needed to accelerate clinically-effective CNS drug discovery. This is the third volume in the three volume-set, Animal and Translational Models for CNS Drug Discovery 978-0-12-373861-5, which is also available for purchase individually.